The latest data on onychomycosis prevalence, risk factors, and treatment trends.
Last Updated: March 20, 2026 · Medically Reviewed Content
Nail fungus (onychomycosis) is far more common than most people realize. According to the American Academy of Dermatology, it affects approximately 10% of the general population, 20% of people over 60, and nearly 50% of people over 70. It’s one of the most common nail conditions worldwide and one of the most stubbornly difficult to treat.
The nail plate acts as a physical barrier that prevents most topical treatments from reaching the infection beneath. Fungal spores embed deep in the nail bed where they’re protected from surface-level creams. Additionally, toenails grow at approximately 1mm per month, meaning it can take 6-12 months for a completely new toenail to grow in — even after the infection is eliminated. This slow growth rate is why patience and consistent treatment are essential for any antifungal approach.
Risk increases with age due to reduced blood circulation, slower nail growth, and years of fungal exposure. Diabetes, peripheral vascular disease, and weakened immune systems significantly increase susceptibility. Lifestyle factors include wearing closed-toe shoes for extended periods, using communal showers (gyms, pools), excessive foot sweating, and previous nail injuries. Athletes are particularly vulnerable.
A growing concern in dermatology is antifungal resistance. Overuse of synthetic antifungal agents has led to fungal strains that no longer respond to conventional treatments. This is one reason why natural antifungal approaches using plant-based compounds like tea tree oil and undecylenic acid are gaining scientific interest — fungi have not developed resistance to these botanicals after centuries of use.
Products like Kerassentials leverage this advantage by combining multiple plant-based antifungal compounds, making it harder for fungi to develop resistance to the multi-pronged approach.
Americans spend over $2.5 billion annually on antifungal treatments, including prescription medications, OTC products, and doctor visits. The average cost of oral prescription antifungal treatment (terbinafine) ranges from $200-$500 for a full course, plus the cost of required liver function blood tests every 4-6 weeks during treatment. This economic reality drives many consumers toward more affordable natural alternatives that don’t require medical monitoring.
Men are affected approximately twice as often as women. Diabetes patients face a 3x higher risk due to impaired circulation and immune function. Athletes, particularly swimmers and runners, are disproportionately affected due to prolonged exposure to moisture and communal facilities. People who work in environments requiring closed-toe safety shoes for extended hours — construction, healthcare, food service — also face elevated risk.
Perhaps most concerning is the psychological impact. Studies show that nail fungus significantly affects quality of life, self-esteem, and social behavior. Many sufferers avoid situations where their feet might be visible — beaches, pools, yoga classes — leading to social isolation and reduced physical activity that compounds other health issues.
A Cochrane systematic review of topical treatments for fungal infections (PMC7073424) analyzed 56 studies covering 12,501 participants and found that most topical treatments have limited efficacy for nail fungus specifically. The review noted that “there is little evidence that topical anti-fungals are effective in the management of onychomycosis” when used as surface creams — highlighting the importance of delivery systems that can penetrate the nail plate, such as oil-based formulations.
Ex vivo nail penetration studies (PMC11393267) have demonstrated significant differences in how various antifungal compounds penetrate the nail plate. Oil-based solutions consistently showed better keratin penetration than water-based creams, confirming the theoretical advantage of oil-based delivery systems like Kerassentials.
Understanding realistic success rates helps set appropriate expectations. Oral terbinafine achieves mycological cure in approximately 70-76% of cases after 12-16 weeks of treatment. Oral itraconazole achieves roughly 54-63%. Prescription topical ciclopirox lacquer achieves only about 29-36% complete cure after 48 weeks. These numbers illustrate why nail fungus is considered one of the most challenging common infections to treat — and why many patients require multiple treatment attempts or combination approaches.
Natural antifungal oils have shown mixed but promising results in clinical trials. The Buck et al. tea tree oil study (PMID: 8195735) showed 60% clinical improvement comparable to prescription clotrimazole. A Vitamin E + essential oil nail treatment achieved 78.5% complete cure over 12 months (PMC6995982). These results suggest that well-formulated natural topical treatments can achieve meaningful outcomes, particularly for mild-to-moderate infections.
The systematic review of complementary and alternative therapies for onychomycosis (PMC9274952) specifically noted the growing concern of antifungal resistance as a reason to investigate natural alternatives. Dermatophyte strains resistant to terbinafine — the most commonly prescribed oral antifungal — have been documented in several countries. This trend makes botanical antifungals like tea tree oil increasingly relevant as complementary or alternative treatment options.
Unlike synthetic antifungals that target single molecular pathways, natural essential oils contain dozens to hundreds of bioactive compounds that attack fungi through multiple mechanisms simultaneously. This complexity makes the development of resistance extremely unlikely — a significant long-term advantage for botanical-based treatments. Products like Kerassentials that combine multiple natural antifungal compounds further reduce resistance risk through their multi-pronged approach.